FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

| OMB APPROVAL | | | | | | | |
|-------------------------|-----------|--|--|--|--|--|--|
| OMB Number: | 3235-0287 | | | | | | |
| Estimated average burde | en | | | | | | |
| hours per response: | 0.5 | | | | | | |

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

| | nd Address of on Lori A | Reporting Person* | | 2. Issuer Name and Ticker or Trading Symbol AMGEN INC [AMGN] | | | | | | | | | ck all applica Director | able) | Perso | on(s) to Issu 10% Ow Other (s | wner | | |
|---|---|--|--|---|--|---|------|---|------|--------------------|---|--------------------------|-------------------------------------|--|---|-------------------------------------|--|---|--|
| (Last) (First) (Middle) ONE AMGEN CENTER DRIVE | | | | | | 3. Date of Earliest Transaction (Month/Day/Year) 05/03/2019 | | | | | | | | Officer (give title below) | | p, HR | | респу | |
| (Street) THOUSAND CA 91320-1799 OAKS | | | | | 4. If Amendment, Date of Original Filed (Month/Day/Year) | | | | | | | | Line) | Individual or Joint/Group Filing (Check Applicable ine) X Form filed by One Reporting Person Form filed by More than One Reporting Person | | | | | |
| (City) (State) (Zip) | | | | | ative Securities Acquired, Disposed of, or Benefic | | | | | | | | | | | | | | |
| | | Tal | ole I - Non- | Derivat | ive Se | curitie | s Ac | quired, E | Disp | osed of | f, or Be | nefi | cially | Owned | | | | | |
| Date | | | | 2. Transact Date (Month/Day | 1 | 2A. Deemed Execution Date, if any (Month/Day/Year) | | 3. Transaction Code (Instr. 8) 4. Securities Acquired (A Disposed Of (D) (Instr. 3, 5) 8) | | | | 4 and Securitie Benefici | | es Forr ally (D) (Following (I) (I | | n: Direct or Indirect nstr. 4) | 7. Nature of Indirect Beneficial Ownership | | |
| | | | | | | | | Code | v | Amount | (A) o | r Pi | ice Reporte Transac (Instr. 3 | | ion(s) | | | (Instr. 4) | |
| Common | Stock | | 05/03/2 | 3/2019 | | A | | 2,030 ⁽¹⁾ A | | | \$0 | 18,535(2)(3) | | | D | | | | |
| | | | Table II - D (e | | | | | uired, Dis , options | | | | | | Owned | | | | | |
| 1. Title of Derivative Security (Instr. 3) | 2. Conversion or Exercise Price of Derivative Security | 3. Transaction Date (Month/Day/Year) | 3A. Deemed Execution Dat if any (Month/Day/Ye | Code | saction e (Instr. | | | 6. Date Exercisable and Expiration Date (Month/Day/Year) | | | 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) | | | 8. Price of Derivative Security (Instr. 5) | 9. Number derivative Securities Beneficial Owned Following Reported Transactio (Instr. 4) | ly | 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) | Beneficial Ownership t (Instr. 4) | |
| | | | | Code | e V | (A) | | Date Exercisable | | expiration Date | Title | or | ount nber ires | | | | | | |
| Nqso (Right to Buy) | \$177.31 | 05/03/2019 | | A | | 17,722 | | 05/03/2021 ⁽² | 4) 0 | 5/03/2029 | Common Stock | 17, | 722 | \$0 | 17,722 | 2 | D | | |

Explanation of Responses:

- 1. The Restricted Stock Units (RSUs) were granted pursuant to the Amgen Inc. 2009 Amended and Restated Equity Incentive Plan and vest in three installments of 33%, 33% and 34% on 5/3/2021, 5/3/2022 and 5/3/2023, respectively.
- 2. These share include the following RSUs granted under the Company's equity plans: 2,398 RSUs which vest in two equal installments of 1,199 on 2/7/2020, and 2/7/2021, respectively; 1,319 RSUs which vest in installments of 649 5/1/2020 and 670 on 5/1/2021; 2,028 RSUs which vest in three installments of 669 on 4/27/2021 and 690 on 4/27/2022; and 2,030 which will vest in installments of 669 on 5/3/2021, 670 on 5/3/2022 and 691 on 5/3/2023. Vested RSUs will be paid in shares of the Company's common stock on a one-to-one basis.
- 3. These shares include 288 Dividend Equivalents (DEs) granted pursuant to the Amgen Inc. 2009 Amended and Restated Equity Incentive Plan and subject to a qualifying dividend reinvestment plan. DEs are credited on the reporting person's unvested RSUs and are paid out in shares of the Company's common stock on a one-to-one basis according to the vesting schedule, along with a cash payment for any remaining fractional share amount.
- $4. \ These non-qualified stock options are exercisable in three installments of 33\%, 33\% and 34\% on 5/3/2021, 5/3/2022 and 5/3/2023, respectively.$

<u>/s/ Lori A. Johnston</u> <u>05/07/2019</u>

** Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.